<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211218053444N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-22</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Cycled phototherapy in treatment of neontal jaundice</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of cycled phototherapy with continuous phototherapy in treatment of jaundice in premature VLBW neonates</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61949</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The Infants will be Admitted to the Study by Observing the Inclusion Criteria, Which will be Classified into two Groups, High Risk and Low Risk, based on the State of Intubation, and then Will Be Randomly Divided into two Groups with a Ratio of 1: 1. the First Group will Receive Continuous Phototherapy and the Other Group Will Receive Periodic Phototherapy Beds for 15 Minutes Per Hour, Blinding description: Parents of infants participating in the study will be blinded in one of two groups after obtaining consent .Clinical caregivers are not blinded due to direct involvement with the baby and the need to discontinue phototherapy at the desired time. The researcher ,the assessor and the enlisor  are blind in this study and extract the results from patient records.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Neonatal Jaundice.</hc_freetext>
      <i_freetext>Intervention group: The effect of periodic phototherapy on VLBW neonates                   Control group: Effect of permanent phototherapy on VLBW neonates   . Neonates will be classified into two groups of high risk and low risk based on intubation status and then randomly divided into two groups with a ratio of 1 to 1. The first group will undergo continuous phototherapy and the other group will be subjected to periodic phototherapy bed for 15 minutes per hour. Serum bilirubin total levels (TSB) of newborns will be measured daily for up to seven days after birth and also on the day that phototherapy was administered or stopped in the second week after birth. Also, the average total hours of phototherapy will be recorded in two groups and will be used for statistical comparison .Light-emitting diode phototherapy lamps will be used to irradiate the blue light of the narrow spectrum. The irradiance intensity of phototherapy lamp will be pre-adjusted so that patients receive 22 μW/cm2/nm of light in low settings equal to 33 μW/cm2/nm in high settings .V wave delay in Brainstem auditory-evoked responses (BAERs), a neurotoxicity sensitive marker with bilirubin, is also measured..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Information will be shared, but how it will be published will be announced later</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Jamali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Blvd., Afzalipour Hospital</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913355</zip>
        <telephone>031328000</telephone>
        <email>z.jamali@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahran Jamali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Blvd., Afzalipour Hospital</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913355</zip>
        <telephone>+98 34 3132 8000</telephone>
        <email>z.jamali@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Weight 1000 to 1500 grams
Failure to receive previous phototherapy
Need to receive phototherapy
Age less than 24 hours</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>1 day</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Known hemolytic disease
Asphyxia
Non-bacterial infection overt
Existence of major anomalies
Unstable conditions (arterial blood pH less than 6.8 for more than 2 hours, stable bradycardia associated with hypoxia for more than 2 hours)
Unwanted consent of the baby's parents or legal guardian to enter the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>jaundice</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>زردی نوزادان</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The effect of periodic phototherapy on VLBW neonates                   Control group: Effect of permanent phototherapy on VLBW neonates   . Neonates will be classified into two groups of high risk and low risk based on intubation status and then randomly divided into two groups with a ratio of 1 to 1. The first group will undergo continuous phototherapy and the other group will be subjected to periodic phototherapy bed for 15 minutes per hour. Serum bilirubin total levels (TSB) of newborns will be measured daily for up to seven days after birth and also on the day that phototherapy was administered or stopped in the second week after birth. Also, the average total hours of phototherapy will be recorded in two groups and will be used for statistical comparison .Light-emitting diode phototherapy lamps will be used to irradiate the blue light of the narrow spectrum. The irradiance intensity of phototherapy lamp will be pre-adjusted so that patients receive 22 μW/cm2/nm of light in low settings equal to 33 μW/cm2/nm in high settings .V wave delay in Brainstem auditory-evoked responses (BAERs), a neurotoxicity sensitive marker with bilirubin, is also measured.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Neonatal jaundice rate. Timepoint: Fourteen days. Method of measurement: Serum bilirubin levels.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-03</approval_date>
        <contact_name>Kerman University of Medical Sciences</contact_name>
        <contact_address>Ebn-e-Sina St., Jahad Blvd., Kerman Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
